Inventor · disambiguated record
John Fraser Wright
Also filed as: WRIGHT JOHN F · WRIGHT JOHN FRASER
21 granted patents·14 pending applications·604 citations·filing 1975–2022
95Inventor score
Files withGENZYME CORP8SPARK THERAPEUTICS INC7CHILDRENS HOSPITAL PHILADELPHIA6WRIGHT JOHN FRASER5FMC CORP2
Top patents by PatentIndex Score
35 records- 0197US8137948B2Methods for producing preparations of recombinant AAV virions substantially free of empty capsidsQU GUANG·Filed 2007·Granted Mar 20, 2012·181 cites·8 claims
- 0297US7704721B2Compositions and methods to prevent AAV vector aggregationGENZYME CORP·Filed 2005·Granted Apr 27, 2010·74 cites·11 claims
- 0396US9051542B2Compositions and methods to prevent AAV vector aggregationWRIGHT JOHN FRASER·Filed 2010·Granted Jun 9, 2015·49 cites·6 claims
- 0496US6593123B1Large-scale recombinant adeno-associated virus (rAAV) production and purificationAVIGEN INC·Filed 2000·Granted Jul 15, 2003·110 cites·21 claims
- 0595US9528126B2Methods for producing preparations of recombinant AAV virions substantially free of empty capsidsQU GUANG·Filed 2012·Granted Dec 27, 2016·37 cites·11 claims
- 0692US9408904B2Scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapyWRIGHT JOHN FRASER·Filed 2012·Granted Aug 9, 2016·22 cites·21 claims
- 0791US11261463B2Methods for producing preparations of recombinant AAV virions substantially free of empty capsidsGENZYME CORP·Filed 2019·Granted Mar 1, 2022·3 cites·10 claims
- 0889US10392632B2AAV8 vector with enhanced functional activity and methods of use thereofWRIGHT JOHN FRASER·Filed 2012·Granted Aug 27, 2019·18 cites·22 claims
- 0988US7261544B2Methods for producing preparations of recombinant AAV virions substantially free of empty capsidsGENZYME CORP·Filed 2004·Granted Aug 28, 2007·13 cites·14 claims
- 1081US10994028B2Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture systemCHILDRENS HOSPITAL PHILADELPHIA·Filed 2017·Granted May 4, 2021·1 cites·38 claims
- 1180US2022364111A1Methods for producing preparations of recombinant aav virions substantially free of empty capsidsGENZYME CORP·Filed 2022·Application pending·0 cites
- 1278US4656143AHeterogeneous binding assayBAKER TERENCE S·Filed 1984·Granted Apr 7, 1987·39 cites·4 claims
- 1377US3999420ALens impact hammer apparatus and methodsWRIGHT JOHN F·Filed 1975·Granted Dec 28, 1976·29 cites·18 claims
- 1476US10787681B2Humanized viral vectors and methods of use thereofCHILDRENS HOSPITAL PHILADELPHIA·Filed 2017·Granted Sep 29, 2020·1 cites·12 claims
- 1574US4058067ATreatment of seedlingsFMC CORP·Filed 1976·Granted Nov 15, 1977·27 cites·2 claims
- 1670US11878056B2Scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapyCHILDRENS HOSPITAL PHILADELPHIA·Filed 2020·Granted Jan 23, 2024·0 cites·24 claims
- 1770US2019032081A1Methods for producing preparations of recombinant aav virions substantially free of empty capsidsGENZYME CORP·Filed 2018·Application pending·0 cites
- 1866US2017260545A1Methods for producing preparations of recombinant aav virions substantially free of empty capsidsGENZYME CORP·Filed 2016·Application pending·0 cites
- 1962US2010098666A1Humanized Viral Vectors and Methods of Use ThereofWRIGHT JOHN FRASER·Filed 2009·Application pending·0 cites
- 2062US2017247664A1Compositions and methods to prevent aav vector aggregationGENZYME CORP·Filed 2016·Application pending·0 cites
- 2162US2014323556A1Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture systemPHILADELPHIA CHILDREN HOSPITAL·Filed 2014·Application pending·0 cites
- 2261US2019321463A1Scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapyCHILDRENS HOSPITAL PHILADELPHIA·Filed 2019·Application pending·0 cites
- 2360US11807865B2Large commercial scale lentiviral vector production system and vectors produced therebyCHILDRENS HOSPITAL PHILADELPHIA·Filed 2018·Granted Nov 7, 2023·0 cites·18 claims
- 2459US2016083694A1Compositions and methods to prevent aav vector aggregationGENZYME CORP·Filed 2015·Application pending·0 cites
- 2555US10328145B2Scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapyCHILDRENS HOSPITAL PHILADELPHIA·Filed 2016·Granted Jun 25, 2019·0 cites·24 claims
- 2655US2023144548A1Recombinant aav vectors with altered immunogencity and methods of making the sameWRIGHT JOHN FRASER·Filed 2020·Application pending·0 cites
- 2751US2003207439A1Large-scale recombinant adeno-associated virus (rAAV) production and purificationFiled 2003·Application pending·0 cites
- 2846US2020164008A1Apheresis methods and usesSPARK THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2943US12404526B2Enhancing agents for improved cell transfection and/or rAAV vector productionSPARK THERAPEUTICS INC·Filed 2018·Granted Sep 2, 2025·0 cites·37 claims
- 3043US10633689B2Rab Escort Protein potency assaySPARK THERAPEUTICS INC·Filed 2017·Granted Apr 28, 2020·0 cites·32 claims
- 3142US11702639B2Column-based fully scalable rAAV manufacturing processSPARK THERAPEUTICS INC·Filed 2017·Granted Jul 18, 2023·0 cites·47 claims
- 3242US2019284576A1SCALABLE HIGH RECOVERY METHODS FOR PRODUCING HIGH YIELD RECOMBINANT ADENO-ASSOCIATED VIRAL (rAAV) VECTOR AND RECOMBINANT ADENO-ASSOCIATED VIRAL (rAAV) VECTORS PRODUCED THEREBYSPARK THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3341US2019292561A1Scalable methods for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical useSPARK THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 3438US2019078099A1Cell line for recombinant protein and/or viral vector productionSPARK THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3528US7329690B2Effectiveness of invertebrate pest-control agentsFMC CORP·Filed 2002·Granted Feb 12, 2008·0 cites·11 claims
Join the waitlist — get patent alerts
Get an alert when John Fraser Wright files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →